A REVIEW OF TESTOSTERONE

At the end of their cycle, hematocrit degrees had increased by three%-point in contrast with baseline. The rise was not associated with longer use or larger AAS dose. A basis for this is likely to be that, further than a particular degree of androgenic activity, no further increase of hematocrit takes place: a ‘ceiling outcome’. Notably, wherea